logo
  

CTI BioPharma: FDA Extends Review Period For Pacritinib For Treatment Of Myelofibrosis; Stock Down

CTI BioPharma Corp. (CTIC) said that the U.S. Food and Drug Administration has extended the review period for the New Drug Application or NDA for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis or MF with a baseline platelet count of <50 × 109/L.

The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to February 28, 2022.

CTIC closed Tuesday regular trading at $2.25 down $0.41 or 15.41%. In the after-hours, the stock further dropped $0.42 or 18.67%.

The FDA had granted priority review for CTI's NDA for patients with myelofibrosis with a PDUFA date of November 30, 2021.

In the course of product labeling discussions, the FDA requested additional clinical data, which was submitted to the agency on November 24, 2021.

Earlier today, the FDA informed the company that it considers the data submission to constitute a "major amendment" to the NDA and therefore the PDUFA date has been extended by three months to provide additional time for a full review of the submission.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter Inc. said it is expanding engineering center in Singapore, its Asia Pacific headquarters. The number of engineers there will be doubled to over 100 staff in 2023. Focused on product innovations and improvements, the new hires will work from Singapore on global initiatives for Twitter. These new technical hires will span roles in engineering, data science, machine learning and product... The U.S. Food and Drug Administration (FDA) has granted approval and reissued the revised Emergency Use Authorization (EUA) to Gilead Sciences Inc. for antiviral drug Veklury (remdesivir) to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 disease. Shares of Philips Electronics NV were losing more than 4 percent in the morning trading in Amsterdam as well as in pre- market activity on the NYSE, after the Dutch consumer electronics giant reported lower profit and sales in its fourth quarter. Comparable sales declined, while comparable order intake increased. Further, the company maintained its dividend, and said it expects to start the year
Follow RTT